Program
lanifibranor
Also written as “IVA337” and “Lanifibranor”.
In Sino Biopharmaceutical's pipeline, 泛PPAR激动剂
. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Scleroderma, Diffuse, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Inventiva Pharma | 51 open or running | phase 3since Apr 16, 2021 | Jun 30, 2015 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 1since Nov 7, 2023 | Nov 7, 2023 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
Lanifibranor
, phase 3, as of Nov 16, 2026 (source).
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 30, 2015First study: phase 2 study in Scleroderma, DiffuseNew to Inventiva PharmaInventiva Pharma · NCT02503644 · 145 enrolled · Bulgaria, France, Germany and more
- Dec 22, 2016Phase 2 study in Non-alcoholic Fatty Liver DiseaseInventiva Pharma · NCT03008070 · 247 enrolled · United States, Australia, Austria and more
- Mar 1, 2019Phase 1 study in Healthy SubjectsInventiva Pharma · NCT03866369 · 36 enrolled · Germany
- Apr 16, 2021Phase 3 study in Non-alcoholic Fatty Liver DiseaseInventiva Pharma · NCT04849728 · 1,000 enrolled · United States, Argentina, Australia and more
- Jan 26, 2022Phase 2 study in Non-alcoholic Fatty Liver DiseaseInventiva Pharma · NCT05232071 · 39 enrolled · United States, Belgium, France and more
- Nov 7, 2023Sino Biopharmaceutical's first study: phase 1 study in PharmacokineticNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT06126562 · 24 enrolled · China
TargetBeta
“泛PPAR激动剂”the company's pipeline, read by Claude · source
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06126562Pharmacokinetic · China | 1 | Completed | Sino Biopharmaceutical | Nov 28, 2023 | 24 |
| NCT05232071Non-alcoholic Fatty Liver Disease · United States, Belgium, France and more | 2 | Completed | Inventiva Pharma | May 8, 2024 | 39 |
| NCT04849728Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Inventiva Pharma | Sep 29, 2026 | 1,000 |
| NCT03866369Healthy Subjects · Germany | 1 | Completed | Inventiva Pharma | Aug 27, 2019 | 36 |
| NCT03008070Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more | 2 | Completed | Inventiva Pharma | Feb 20, 2020 | 247 |
| NCT02503644Scleroderma, Diffuse · Bulgaria, France, Germany and more | 2 | Completed | Inventiva Pharma | Oct 2018 | 145 |
How it is read
Names in the registry
- “IVA337”, 4 entries
- “Lanifibranor”, 3 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 3 studies
- Scleroderma, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.